NCT06597539 The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Hepatobiliary Malignancy
| NCT ID | NCT06597539 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ruijin Hospital |
| Condition | Hepatobiliary Malignancy |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2024-11-09 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2024-11-09 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced hepatobiliary malignancies.
Eligibility Criteria
Inclusion Criteria: 1. Pathological and clinical diagnosis of advanced hepatobiliary malignancy requiring immunotherapy or combination immunotherapy after evaluation according to clinical guidelines 2. Signed and dated informed consent form 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process 4. aged 18-75 years old 5. The patient is in good general condition with an expected survival of \> 6 months Exclusion Criteria: 1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Uncontrolled diabetes patients or fasting blood glucose levels ≥11 mmol/L on the day of the trial 4. Pregnant women and women who may be pregnant, women who are breastfeeding. 5. Non-compliant person
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06597539 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Hepatobiliary Malignancy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06597539 currently recruiting?
Yes, NCT06597539 is actively recruiting participants. Contact the research team at jiajiahu@shsmu.edu.cn for enrollment information.
Where is the NCT06597539 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT06597539 clinical trial?
NCT06597539 is sponsored by Ruijin Hospital. The trial plans to enroll 40 participants.